Evidence Table 84. KQ2—Continuous data—Proteinuria

| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/. Control** | **N** | **Definition of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ferraro 200922  parallel | Unclear | ramipril | 10 | Omega-3 (EPA, DHA, or both). | 15 | UPE (urinary protein excersion)  baseline was considered a mean of the positive measurements obtained before the final period. | Mean: 367  Median  SD: 520  SE:  Lower:  Upper: | Mean:  % mean: -77.9  Median:  SD:  P: | Mean:-61.6  Median:  SD:  P:<0.01 |  | medium |
|  | No treatment (aside from CVD drug) | 15 | Mean:1353  Median  SD: 1304 | Mean:  % mean: -11.3 |